查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579332

急性肺損傷治療市場：按治療類型、劑型、醫療保健提供者、診斷分類 - 2025-2030 年全球預測

Acute Lung Injury Treatment Market by Treatment Type (Non-Pharmacological Interventions, Pharmacotherapy, Surgical Intervention), Dosage Form (Inhalation, Injectable, Intravenous), Healthcare Provider, Diagnosis - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年急性肺損傷治療市場規模為31億美元，預計2024年將達32.2億美元，複合年成長率為4.16%，2030年將達41.3億美元。

急性肺損傷 (ALI) 治療市場包括藥品、醫療設備和旨在控制和緩解 ALI 患者症狀的治療方法，ALI 的特徵是肺部廣泛發炎迅速發作。 ALI 相關的高發病率和死亡率所需的治療應用包括針對潛在病理學過程的通氣支持和藥物干預。最終用途範圍主要包括專注於肺部健康的醫院、診所和研究機構，而此類治療對於管理不同患者群體的急性呼吸窘迫至關重要。影響市場的關鍵成長要素包括肺炎、敗血症和創傷等風險因素的日益流行，以及生物技術和再生醫學的進步推動治療通訊協定的創新。成長機會在於開發個人化醫療方法，利用先進的基因組學和生物標記識別來有效客製化治療方法。此外，人工智慧和機器學習在診斷和治療結果預測中的整合提供了另一個值得探索的沃土。

主要市場統計
基準年[2023] 31億美元
預測年份 [2024] 32.2億美元
預測年份 [2030] 41.3億美元
複合年成長率（%） 4.16%

然而，由於目前的治療方法通常是支持性的而不是治癒性的，缺乏具體的治療方案和先進治療方案的高成本限制了全球醫療保健系統，例如給該國帶來了經濟挑戰。有關藥物開發和核准的嚴格監管要求也可能阻礙市場成長。市場面臨治療效果的可變性和 ALI 複雜的病理學的挑戰，這使得普遍有效的治療方法的開發變得複雜。需要創新的領域包括發炎藥物研究、幹細胞治療以及奈米技術在肺部標靶藥物傳遞的應用。儘管有這些挑戰，ALI 治療市場仍充滿活力，需要臨床研究、生技公司和醫療保健提供者之間的合作，以最佳化治療方法並改善患者的治療結果。最終，適應監管環境和投資尖端研究對於企業的持續成長和市場領導地位至關重要。

市場動態：快速發展的急性肺損傷治療市場的關鍵市場洞察

供需的動態交互作用正在改變急性肺損傷治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 急性肺損傷的盛行率不斷增加，人們對早期診斷和治療方案的認知不斷提高
    • 政府和私人對醫療基礎設施和肺部相關疾病研究進行了大量投資
    • 擴大非侵入性通氣策略和個人化醫療在急性肺損傷治療的採用
  • 市場限制因素
    • 核准新的急性肺損傷治療方法的嚴格監管要求
  • 市場機會
    • 發展急性肺損傷治療的個人化醫療方法，以改善患者的治療效果
    • 利用人工智慧和機器學習進行急性肺損傷治療和管理的預測分析
  • 市場挑戰
    • 醫療保健專業人員和患者缺乏對急性肺損傷的認知和早期診斷

波特五力：開拓急性肺損傷治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解急性肺損傷治療市場的外部影響

外部宏觀環境因素在塑造急性肺損傷治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解急性肺損傷治療市場的競爭格局

對急性肺損傷治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣急性肺損傷治療市場供應商的績效評估

FPNV 定位矩陣是評估急性肺損傷治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃急性肺損傷治療市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對急性肺損傷治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 急性肺損傷盛行率增加，人們對早期診斷和治療方案的認知提高
      • 政府和私人對醫療基礎設施和肺部相關疾病研究進行了大量投資
      • 在急性肺損傷的治療中更多地採用非侵入性通氣策略和個人化醫療
    • 抑制因素
      • 急性肺損傷新治療方法的核准需要嚴格的監管要求
    • 機會
      • 發展急性肺損傷治療的個人化醫療方法，以改善患者的治療效果
      • 使用人工智慧和機器學習對急性肺損傷治療進行預測分析和管理
    • 任務
      • 醫護人員和病人缺乏對急性肺損傷的認知和早期診斷
  • 市場區隔分析
    • 治療類型：

第 5 章 2.2。

  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的急性肺損傷治療市場

  • 非藥物干預
    • 體液管理
    • 通氣輔助
  • 藥物治療
    • 抗生素
    • 皮質類固醇
    • 利尿劑
    • 黏液溶解藥物
  • 手術介入
    • 支氣管鏡檢查
    • 體外膜氧合（ECMO）
    • 肺移植

第7章依劑型分類的急性肺損傷治療市場

  • 吸入
  • 可注射的
  • 靜脈
  • 口服

第8章醫療保健提供者的急性肺損傷治療市場

  • 診所
    • 基層醫療診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 調查機構
    • 政府研究中心
    • 大學醫院

第9章 急性肺損傷診斷治療市場

  • 驗血
  • 支氣管鏡檢查
  • 影像檢查
    • 胸部X光檢查
    • 電腦斷層掃描
  • 氧氣濃度測量

第10章美洲急性肺損傷治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區急性肺損傷治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲急性肺損傷治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准RYBREVANT 和 LAZCLUZE 合併用藥代表 EGFR 突變肺癌治療的重大進展
    • GSK 以 14 億美元收購 Aiolos Bio，透過創新氣喘治療加強呼吸系統產品線
    • Aegis Therapeutics 從 BARDA 獲得 2000 萬美元，用於推進 ARDS 治療的 2 期試驗
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Bayer AG
  • BioLineRx Ltd.
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring LLC.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Lisata Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Synairgen plc
  • Takeda Pharmaceutical Company Limited
  • Windtree Therapeutics, Inc.
Product Code: MRR-1A1A064C0344

The Acute Lung Injury Treatment Market was valued at USD 3.10 billion in 2023, expected to reach USD 3.22 billion in 2024, and is projected to grow at a CAGR of 4.16%, to USD 4.13 billion by 2030.

The scope of the Acute Lung Injury (ALI) Treatment market encompasses pharmaceuticals, medical devices, and therapeutic modalities aimed at managing or alleviating symptoms in patients suffering from ALI, a condition characterized by rapid onset of widespread inflammation in the lungs. Necessitated by the high morbidity and mortality associated with ALI, treatment applications include ventilatory support and pharmaceutical interventions targeting the underlying pathophysiological processes. The end-use scope primarily involves hospitals, clinics, and research institutes focusing on pulmonary health, where such treatments are critical for managing acute respiratory distress in diverse patient demographics. Key growth factors influencing the market include increasing prevalence of risk factors such as pneumonia, sepsis, and trauma, coupled with advancements in biotechnology and regenerative medicine, which foster innovations in treatment protocols. Opportunities for growth lie in the development of personalized medicine approaches, leveraging advanced genomics and biomarker identification to tailor treatments effectively. Furthermore, the integration of AI and machine learning in predictive diagnostics and therapeutic outcomes presents another fertile area for exploration.

KEY MARKET STATISTICS
Base Year [2023] USD 3.10 billion
Estimated Year [2024] USD 3.22 billion
Forecast Year [2030] USD 4.13 billion
CAGR (%) 4.16%

However, limitations include a lack of specific treatment protocols, as current therapies are often supportive rather than curative, and the high cost of advanced therapeutic options poses economic challenges to healthcare systems globally. Stringent regulatory requirements for drug development and approval can also hinder market growth. The market faces challenges from variability in treatment responses and the complex pathogenesis of ALI, which complicates the development of universally effective treatments. Areas ripe for innovation include the research into anti-inflammatory drugs, stem-cell therapy, and the application of nanotechnology for targeted drug delivery to the lungs. Despite these challenges, the ALI treatment market is dynamic, with a forward-looking approach necessitating collaboration between clinical research, biotechnology firms, and healthcare providers to optimize treatment modalities and improve patient outcomes. Ultimately, navigating regulatory landscapes and investing in cutting-edge research are crucial for sustained business growth and market leadership.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Lung Injury Treatment Market

The Acute Lung Injury Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of acute lung injury and rising awareness about early diagnosis and treatment options
    • Significant government and private investments in healthcare infrastructure and research for lung-related diseases
    • Growing adoption of non-invasive ventilation strategies and personalized medicine to manage acute lung injury
  • Market Restraints
    • Strict regulatory requirements for approval of new acute lung injury treatments
  • Market Opportunities
    • Developing personalized medicine approaches for acute lung injury treatment to improve patient outcomes
    • Leveraging AI and machine learning for predictive analytics in acute lung injury treatment and management
  • Market Challenges
    • Lack of awareness and early diagnosis of acute lung injury among healthcare professionals and patients

Porter's Five Forces: A Strategic Tool for Navigating the Acute Lung Injury Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Lung Injury Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Lung Injury Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Lung Injury Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Lung Injury Treatment Market

A detailed market share analysis in the Acute Lung Injury Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Lung Injury Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Lung Injury Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Lung Injury Treatment Market

A strategic analysis of the Acute Lung Injury Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Lung Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, BioLineRx Ltd., Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., CSL Behring LLC., Eli Lilly and Company, FibroGen, Inc., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Lisata Therapeutics, Inc., Merck & Co., Inc., Mesoblast Limited, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Synairgen plc, Takeda Pharmaceutical Company Limited, and Windtree Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Acute Lung Injury Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Non-Pharmacological Interventions, Pharmacotherapy, and Surgical Intervention. The Non-Pharmacological Interventions is further studied across Fluid Management and Ventilatory Support. The Pharmacotherapy is further studied across Antibiotics, Corticosteroids, Diuretics, and Mucolytics. The Surgical Intervention is further studied across Bronchoscopy, Extracorporeal Membrane Oxygenation (ECMO), and Lung Transplant.
  • Based on Dosage Form, market is studied across Inhalation, Injectable, Intravenous, and Oral.
  • Based on Healthcare Provider, market is studied across Clinics, Hospitals, and Research Institutes. The Clinics is further studied across Primary Care Clinics and Specialized Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Research Institutes is further studied across Government Research Centers and University Hospitals.
  • Based on Diagnosis, market is studied across Blood Tests, Bronchoscopy, Imaging Tests, and Oximetry. The Imaging Tests is further studied across Chest X-Ray and CT Scan.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of acute lung injury and rising awareness about early diagnosis and treatment options
      • 5.1.1.2. Significant government and private investments in healthcare infrastructure and research for lung-related diseases
      • 5.1.1.3. Growing adoption of non-invasive ventilation strategies and personalized medicine to manage acute lung injury
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory requirements for approval of new acute lung injury treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing personalized medicine approaches for acute lung injury treatment to improve patient outcomes
      • 5.1.3.2. Leveraging AI and machine learning for predictive analytics in acute lung injury treatment and management
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and early diagnosis of acute lung injury among healthcare professionals and patients
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type:

5.2.2. Diagnosis:

  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Lung Injury Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Interventions
    • 6.2.1. Fluid Management
    • 6.2.2. Ventilatory Support
  • 6.3. Pharmacotherapy
    • 6.3.1. Antibiotics
    • 6.3.2. Corticosteroids
    • 6.3.3. Diuretics
    • 6.3.4. Mucolytics
  • 6.4. Surgical Intervention
    • 6.4.1. Bronchoscopy
    • 6.4.2. Extracorporeal Membrane Oxygenation (ECMO)
    • 6.4.3. Lung Transplant

7. Acute Lung Injury Treatment Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Injectable
  • 7.4. Intravenous
  • 7.5. Oral

8. Acute Lung Injury Treatment Market, by Healthcare Provider

  • 8.1. Introduction
  • 8.2. Clinics
    • 8.2.1. Primary Care Clinics
    • 8.2.2. Specialized Clinics
  • 8.3. Hospitals
    • 8.3.1. Private Hospitals
    • 8.3.2. Public Hospitals
  • 8.4. Research Institutes
    • 8.4.1. Government Research Centers
    • 8.4.2. University Hospitals

9. Acute Lung Injury Treatment Market, by Diagnosis

  • 9.1. Introduction
  • 9.2. Blood Tests
  • 9.3. Bronchoscopy
  • 9.4. Imaging Tests
    • 9.4.1. Chest X-Ray
    • 9.4.2. CT Scan
  • 9.5. Oximetry

10. Americas Acute Lung Injury Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Lung Injury Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Lung Injury Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA approval of RYBREVANT and LAZCLUZE combination offers significant advancement in EGFR-mutated lung cancer treatment
    • 13.3.2. GSK's USD 1.4 billion acquisition of Aiolos Bio boosts respiratory pipeline with innovative asthma treatment
    • 13.3.3. BioAegis Therapeutics secures USD 20 million from BARDA to advance phase 2 study for ARDS treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. BioLineRx Ltd.
  • 4. Boehringer Ingelheim GmbH
  • 5. Chiesi Farmaceutici S.p.A.
  • 6. CSL Behring LLC.
  • 7. Eli Lilly and Company
  • 8. FibroGen, Inc.
  • 9. Genentech, Inc.
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Hoffmann-La Roche Ltd.
  • 13. Lisata Therapeutics, Inc.
  • 14. Merck & Co., Inc.
  • 15. Mesoblast Limited
  • 16. Novartis International AG
  • 17. Pfizer Inc.
  • 18. Regeneron Pharmaceuticals, Inc.
  • 19. Sanofi S.A.
  • 20. Synairgen plc
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Windtree Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ACUTE LUNG INJURY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACUTE LUNG INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACUTE LUNG INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE LUNG INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE LUNG INJURY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VENTILATORY SUPPORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY LUNG TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY UNIVERSITY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OXIMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 295. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 306. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE ACUTE LUNG INJURY T